RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment.

•Monocyte-myeloid derived suppressed cells (M-MDSCs) plays a significant role in immune suppression and contributed to cancer progression, which was increased in bladder cancer (BC) tissue.•This article helps us understand the immune environment of BC deeply.•Gemcitabine treatment promotes the generation of CCL2 in BC cells, which could recruit M-MDSCs.•This shortage influences the prognosis of BC patients.•RS 504393, a selective CCR2 antagonist, sheds lights on preventing and alleviating side effects of the symptoms occurred on the gemcitabine-treated BC patients, which can improve prognosis of gemcitabine-treated BC patients.